|
May 18, 2022
|
Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)
|
|
May 9, 2022
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
|
|
May 2, 2022
|
Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022
|
|
March 29, 2022
|
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
|
|
March 8, 2022
|
Enanta Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
|
|
February 17, 2022
|
Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)
|
|
February 16, 2022
|
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
|
|
February 10, 2022
|
Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference
|
|
February 8, 2022
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
|
|
February 1, 2022
|
Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021
|